Abstract: AbstractObjectivesMany patients with haemoglobinopathies, including thalassaemia and sickle cell disease, are at increased risk of developing severe complications from the coronavirus disease 2019 (COVID‐19). Although epidemiologic evidence concerning the novel coronavirus (SARS‐CoV‐2) infection in these patients is currently lacking, the COVID‐19 pandemic represents a significant challenge for haemoglobinopathy patients, their families and their attending physicians.MethodsThe present statement summarizes the key challenges concerning ...
(read more)
Topics: 
Intensive care medicine
Pediatrics